Syndax Pharmaceuticals (SNDX)
(Real Time Quote from BATS)
$23.50 USD
+0.22 (0.95%)
Updated Jul 24, 2024 11:20 AM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Syndax Pharmaceuticals (SNDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$35.31 | $45.00 | $23.00 | 51.68% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Syndax Pharmaceuticals comes to $35.31. The forecasts range from a low of $23.00 to a high of $45.00. The average price target represents an increase of 51.68% from the last closing price of $23.28.
Analyst Price Targets (13)
Broker Rating
Syndax Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 13 are Strong Buy, representing 92.86% of all recommendations. A month ago, Strong Buy represented 92.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/14/2024 | Scotiabank | George Farmer | Strong Buy | Hold |
6/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
3/27/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
3/1/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
10/11/2023 | Goldman Sachs | Chris Shibutani | Not Available | Strong Buy |
10/3/2023 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 14 |
Average Target Price | $35.31 |
LT Growth Rate | 28.60% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -0.91 |